Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 30 results.
User Information
Export Records
  1. 1.   CD19-positive antibody-secreting cells provide immune memory
  2. Groves, C. J.; Carrell, Jeff; Grady, R.; Rajan, B.; Morehouse, C. A.; Halpin, R.; Wang, J.; Wu, J.; Shrestha, Y.; Rayanki, R.; Kolbeck, R.; Wang, Y.; Herbst, R.
  3. Blood advances. 2018, NOV 27; 2(22): 3163-3176.
  1. 2.   Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies
  2. Nayar, Utthara; Sadek, Jouliana; Reichel, Jonathan; Hernandez-Hopkins, Denise; Akar, Gunkut; Barelli, Peter J.; Sahai, Michelle A.; Zhou, Hufeng; Totonchy, Jennifer; Jayabalan, David; Niesvizky, Ruben; Guasparri, Ilaria; Hassane, Duane; Liu, Yifang; Sei, Shizuko; Shoemaker, Robert; Warren, J. David; Elemento, Olivier; Kaye, Kenneth M.; Cesarman, Ethel
  3. JOURNAL OF CLINICAL INVESTIGATION. 2017, Jun; 127(6): 2066-2080.
  1. 3.   Antitumor Activity of a Novel Oncrasin Analogue Is Mediated by JNK Activation and STAT3 Inhibition
  2. Guo, W.; Wu, S. H.; Wang, L.; Wei, X. L.; Liu, X. Y.; Wang, J.; Lu, Z. M.; Hollingshead, M.; Fang, B. L.
  3. Plos One. 2011, Dec; 6(12):
  1. 4.   Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
  2. Lee, S.; Yagita, H.; Sayers, T. J.; Celis, E.
  3. Cancer Immunology Immunotherapy. 2010, Jul; 59(7): 1073-1081.
  1. 5.   The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
  2. Lucas, D. M.; Edwards, R. B.; Lozanski, G.; West, D. A.; Shin, J. D.; Vargo, M. A.; Davis, M. E.; Rozewski, D. M.; Johnson, A. J.; Su, B. N.; Goettl, V. M.; Heerema, N. A.; Lin, T. S.; Lehman, A.; Zhang, X. L.; Jarjoura, D.; Newman, D. J.; Byrd, J. C.
  3. Blood. 2009 113(19): 4656-4666.
  1. 6.   Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
  2. Sissung, T. M.; Thordardottir, S.; Gardner, E. R.; Figg, W. D.
  3. Anti-cancer agents in medicinal chemistry. 2009 9(10): 1058-1069.
  1. 7.   Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
  2. Hallett, W.; Ames, E.; Motarjemi, M.; Barao, I.; Shanker, A.; Tamang, D. L.; Sayers, T. J.; Hudig, D.; Murphy, W. J.
  3. Journal of Immunology. 2008 180(1): 163-170.
  1. 8.   Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Wine, J. W.; Elliott, P. J.; Yagita, H.; Takeda, K.; Smyth, M. J.; Murphy, W. J.; Sayers, T. J.
  3. Journal of the National Cancer Institute. 2008 100(9): 649-662.
  1. 9.   One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia
  2. Lee, K. M.; Lan, Q.; Kricker, A.; Purdue, M. P.; Grulich, A. E.; Vajdic, C. M.; Turner, J.; Whitby, D.; Kang, D.; Chanock, S.; Rothman, N.; Armstrong, B. K.
  3. Human Genetics. 2007, Dec; 122(5): 525-533.
  1. 10.   Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines
  2. Hurt, E. M.; Thomas, S. B.; Peng, B.; Farrar, W. L.
  3. British Journal of Cancer. 2007, Oct; 97(8): 1116-1123.
  1. 11.   Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo
  2. Gills, J.; Lo Piccolo, J.; Tsurutani, J.; Shoemaker, R. H.; Best, C. J. M.; Abu-Asab, M. S.; Borojerdi, J.; Warfel, N. A.; Gardner, E. R.; Danish, M.; Hollander, M. C.; Kawabata, S.; Tsokos, M.; Figga, W. D.; Steeg, P. S.; Dennis, P. A.
  3. Clinical Cancer Research. 2007, Sep; 13(17): 5183-5194.
  1. 12.   Thalidomide analogues as anticancer drugs
  2. Aragon-Ching, J. B.; Li, H. Q.; Gardner, E. R.; Figg, W. D.
  3. Recent Patents on Anti-Cancer Drug Discovery. 2007, Jun; 2(2): 167-174.
  1. 13.   Importance of the stress kinase p38 alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells
  2. Warfel, N. A.; Lepper, E. R.; Zhang, C. Y.; Figg, W. D.; Dennis, P. A.
  3. Clinical Cancer Research. 2006, Jun; 12(11): 3502-3509.
  1. 14.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 15.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 16.   JS-K, a GST-activated nitric oxide generator, induces apoptosis and overcomes in vitro drug resistance in multiple myeloma cells
  2. Kiziltepe, T.; Ishitsuka, K.; Hideshima, T.; Raje, N.; Shiraishi, N.; Yasui, H.; Catley, L.; Chauhan, D.; Saavedra, J. E.; Keefer, L. K.; Shami, P. J.; Anderson, K. C.
  3. Blood. 2005, NOV 16; 106(11, Part 1): 456A, Abstract 1593-456A, Abstract 1593.
  1. 17.   The role of IL-6 and STAT3 in inflammation and cancer
  2. Hodge, D. R.; Hurt, E. M.; Farrar, W. L.
  3. European Journal of Cancer. 2005, NOV; 41(16): 2502-2512.
  1. 18.   Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation
  2. Hodge, D. R.; Peng, B.; Cherry, J. C.; Hurt, E. M.; Fox, S. D.; Kelley, J. A.; Munroe, D. J.; Farrar, W. L.
  3. Cancer Research. 2005, JUN 1; 65(11): 4673-4682.
  1. 19.   Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells
  2. Pengt, B.; Hodge, D. R.; Thomas, S. B.; Cherry, J. M.; Munroe, D. J.; Pompeia, C.; Xiao, W. H.; Farrar, W. L.
  3. Journal of Biological Chemistry. 2005, FEB 11; 280(6): 4182-4187.
  1. 20.   Nuclear receptors as negative modulators of STAT3 in multiple myeloma
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Cell Cycle. 2005, FEB; 4(2): 242-245.
  1. 21.   Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
  2. Neelapu, S. S.; Munshi, N. C.; Jagannath, S.; Watson, T. M.; Pennington, R.; Barlogie, B.; Kwak, L. W.
  3. Blood. 2004, NOV 16; 104(11, Part 1, Abstract 3340): 913A-913A.
  1. 22.   NF-kappa B activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NF kappa B regulatory site in autocrine human multiple myeloma cells
  2. Xiao, W. H.; Hodge, D. R.; Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004, OCT; 3(10): 1007-1017.
  1. 23.   Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells
  2. Hodge, D. R.; Xiao, W. H.; Wang, L. H.; Li, D. P.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004 3(2): 188-194.
  1. 24.   Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line
  2. Pompeia, C.; Hodge, D. R.; Plass, C.; Wu, Y. Z.; Marquez, V. E.; Kelley, J. A.; Farrar, W. L.
  3. Cancer Research. 2004 64(10): 3465-3473.
  1. 25.   Transcriptional inactivation of STAT3 by PPAR gamma suppresses IL-6-responsive multiple myeloma cells
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Huang, J. Q.; Hou, J.; Li, J.; Xiong, H.; Mihalic, K.; Zhu, H. M.; Xiao, W. H.; Farrar, W. L.
  3. Immunity. 2004 20(2): 205-218.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel